Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform
The microfluidics-based system accommodates scalable throughputs to address specific and evolving project needs SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human
View HTML
Toggle Summary Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of August 22, 2022 , under the
View HTML
Toggle Summary Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update
Second quarter revenue of $18.8 million Completed $250 million strategic cash infusion from Casdin Capital and Viking Global   Upgraded management team and added board members to bring significant sector and operational expertise to the company   Commenced restructuring program with the explicit
View HTML
Toggle Summary Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif. , July 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after
View HTML
Toggle Summary Standard BioTools Announces First Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif. , May 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health  – today announced financial results for the first quarter ended March 31, 2022 .   “The end of first quarter
View HTML
Toggle Summary Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif. , April 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after
View HTML
Toggle Summary Standard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging
Capacity to Process 100-Plus Samples per Week, with 1.6x Lower Limit of Detection SOUTH SAN FRANCISCO, Calif. , April 11, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health – today announced the
View HTML
Toggle Summary Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , April 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (f/k/a Fluidigm Corporation) (Nasdaq:FLDM) today announced, as required by Nasdaq Stock Market Rules, the grant of equity inducement awards to its new executive officers Michael Egholm , the Company’s new
View HTML
Toggle Summary Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
SOUTH SAN FRANCISCO, Calif. , April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital,
View HTML